A new trend is underway that is bringing jobs back to the US. But one company was ahead of the curve: Unilife Corporation, a developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania.
In a Fox Business interview, Unilife CEO Alan Shortall explains that the company had outsourced its manufacturing operation to China around 2004-2005, but decided to move it back to the United States for a variety of reasons, not all of them intuitive. For example, the US's well-known and very stringent safety regulations, which make most businesses look elsewhere for manufacturing opportunities, were exactly what Unilife Corp was looking for.
As Mr. Shortall explains, "The US has a wonderful reputation for high quality medical devices, and the reason for that is because the regulations in the US are so stringent. Now I know we all complain about regulations, but this is one time when we actually embrace them, because it makes us better. And consequently, we can sell our products anywhere in the world because they're recognized as the best."
About Unilife Corporation
Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS) is a U.S. based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.